466 related articles for article (PubMed ID: 30039289)
21. Neoadjuvant therapy for high-risk bulky regional melanoma.
Tarhini AA; Pahuja S; Kirkwood JM
J Surg Oncol; 2011 Sep; 104(4):386-90. PubMed ID: 21858833
[TBL] [Abstract][Full Text] [Related]
22. Current status and limitations of immunotherapy for breast cancer.
Tokumaru Y; Joyce D; Takabe K
Surgery; 2020 Mar; 167(3):628-630. PubMed ID: 31623855
[No Abstract] [Full Text] [Related]
23. Adjuvant immunotherapy for melanoma.
Thomas D; Bello DM
J Surg Oncol; 2021 Mar; 123(3):789-797. PubMed ID: 33595889
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant Treatments for Advanced Resectable Melanoma.
Liu JY; Lowe M
J Surg Oncol; 2019 Jan; 119(2):216-221. PubMed ID: 30589079
[TBL] [Abstract][Full Text] [Related]
25. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
26. Immune Checkpoint Inhibitor Therapy in Breast Cancer.
Santa-Maria CA; Nanda R
J Natl Compr Canc Netw; 2018 Oct; 16(10):1259-1268. PubMed ID: 30323094
[TBL] [Abstract][Full Text] [Related]
27. Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting.
Herrscher H; Robert C
Curr Opin Oncol; 2020 Mar; 32(2):106-113. PubMed ID: 31876547
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire.
Tarhini A; Lin Y; Lin H; Rahman Z; Vallabhaneni P; Mendiratta P; Pingpank JF; Holtzman MP; Yusko EC; Rytlewski JA; Rao UNM; Ferris RL; Kirkwood JM
J Immunother Cancer; 2018 Oct; 6(1):112. PubMed ID: 30352626
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Recent Advances and Ongoing Challenges.
Body A; Prenen H; Lam M; Davies A; Tipping-Smith S; Lum C; Liow E; Segelov E
Clin Colorectal Cancer; 2021 Mar; 20(1):29-41. PubMed ID: 33531256
[TBL] [Abstract][Full Text] [Related]
30. Nivolumab: A Review in Advanced Melanoma.
Scott LJ
Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
[TBL] [Abstract][Full Text] [Related]
31. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.
Huang AC; Orlowski RJ; Xu X; Mick R; George SM; Yan PK; Manne S; Kraya AA; Wubbenhorst B; Dorfman L; D'Andrea K; Wenz BM; Liu S; Chilukuri L; Kozlov A; Carberry M; Giles L; Kier MW; Quagliarello F; McGettigan S; Kreider K; Annamalai L; Zhao Q; Mogg R; Xu W; Blumenschein WM; Yearley JH; Linette GP; Amaravadi RK; Schuchter LM; Herati RS; Bengsch B; Nathanson KL; Farwell MD; Karakousis GC; Wherry EJ; Mitchell TC
Nat Med; 2019 Mar; 25(3):454-461. PubMed ID: 30804515
[TBL] [Abstract][Full Text] [Related]
32. [Current aspects in the prognosis of advanced melanoma].
Sirokay-Kohlmeyer J
Hautarzt; 2018 Mar; 69(3):249-259. PubMed ID: 29396638
[TBL] [Abstract][Full Text] [Related]
33. Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers.
Oglesby A; Algazi AP; Daud AI
Am J Clin Dermatol; 2019 Dec; 20(6):781-796. PubMed ID: 31228012
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant therapy for melanoma: a promising therapeutic approach and an ideal platform in drug development.
Tarhini AA
Am Soc Clin Oncol Educ Book; 2015; ():e535-42. PubMed ID: 25993220
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant Immune Checkpoint Inhibition in Metastatic Conjunctival Melanoma.
Fan K; Waninger JJ; Yentz S; McLean S; Demirci H
Ophthalmic Plast Reconstr Surg; 2023 Sep-Oct 01; 39(5):e152-e155. PubMed ID: 37207285
[TBL] [Abstract][Full Text] [Related]
36. Neuroendocrine carcinoma of the cervix: a systematic review of the literature.
Tempfer CB; Tischoff I; Dogan A; Hilal Z; Schultheis B; Kern P; Rezniczek GA
BMC Cancer; 2018 May; 18(1):530. PubMed ID: 29728073
[TBL] [Abstract][Full Text] [Related]
37. Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials.
Ascierto PA; Long GV
Lancet Oncol; 2016 Aug; 17(8):1037-1039. PubMed ID: 27324281
[No Abstract] [Full Text] [Related]
38. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
Georganaki M; van Hooren L; Dimberg A
Front Immunol; 2018; 9():3081. PubMed ID: 30627131
[TBL] [Abstract][Full Text] [Related]
39. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
40. How to use neoadjuvant medical treatment to maximize surgery in melanoma.
Amaral T; Tampouri I; Garbe C
Expert Rev Anticancer Ther; 2018 Feb; 18(2):121-130. PubMed ID: 29271674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
